• Explore /
  • Poster
  • / Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse.

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse.

Abstract Poster

Authors

null

Prajwal Boddu

MD Anderson Cancer Center, Houston, TX

Prajwal Boddu , Jeffrey L. Jorgensen , Hagop M. Kantarjian , Gautam Borthakur , Tapan M. Kadia , Naval Guastad Daver , Yesid Alvarado , Naveen Pemmaraju , Prithviraj Bose , Kiran Naqvi , Musa Yilmaz , Sherry Pierce , Mark Brandt , Courtney Denton Dinardo , Elias Jabbour , Guillermo Garcia-Manero , Jorge E. Cortes , Farhad Ravandi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7018)

DOI

10.1200/JCO.2017.35.15_suppl.7018

Abstract #

7018

Poster Bd #

218

Abstract Disclosures

Similar Posters

First Author: Farhad Ravandi

First Author: Mahesh Swaminathan

First Author: Nischala Ammannagari

Poster

2013 ASCO Annual Meeting

Hypomethylating agents as first-line therapy in acute myeloid leukemia (AML).

Hypomethylating agents as first-line therapy in acute myeloid leukemia (AML).

First Author: Samuel D Bailey